Results 141 to 150 of about 11,407 (242)
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
, 2017 Martin Schiestl,1 Markus Zabransky,2 Fritz Sörgel3,4 1Sandoz GmbH, Kundl, Austria; 2Sandoz Biopharmaceuticals, Hexal AG, Holzkirchen, Germany; 3Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany; 4Institute of ...
Zabransky M, Sörgel F, Schiestl M
core
Biosimilars - drugs of the future
, 2014 The article describes the basic terms and definitions relating to biosimilars, generics and original drugs. Also described a brief history of the origin and development of the biotechnology industry and drugs produced using biological objects.
A. V. Bushmanova +3 more
core
Perceptions of Biosimilars among Medical Specialists
, 2015 Full text is available to authenticated members of The University of Auckland only.Biosimilars are a new pharmaceutical development engineered as a cost-effective alternative to biologics.
Hemmington, Amy
core
The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review. [PDF]
Health Sci RepAhmed Z +6 more
europepmc +1 more source
Update on the safety and bioequivalence of biosimilars – focus on enoxaparin
, 2013 Walter Jeske,1 Jeanine M Walenga,1 Debra Hoppensteadt,2 Jawed Fareed2 1Cardiovascular Institute; 2Department of Pathology, Loyola University Chicago, Maywood, IL, USA Abstract: Generic forms of chemically-derived drugs must exhibit chemical identity and ...
Hoppensteadt D +3 more
core
Advances in Biosimilars: A Systematic Review of Machine Learning Applications. [PDF]
Pharmaceuticals (Basel)Duarte V, Bas TG.
europepmc +1 more source
Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India. [PDF]
Indian J OphthalmolChakraborty D, Sinha TK, Boral S, Das A.
europepmc +1 more source
Patient out-of-pocket costs and rheumatology biosimilar competition. [PDF]
J Manag Care Spec PharmDayer VW +4 more
europepmc +1 more source